Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 21Completed 10Unknown 6Active not recruiting 4Withdrawn 1Terminated 1Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 7Gastrointestinal 6Other hematologic neoplasm 5Thoracic 4Breast 4Genitourinary 3Tumor-Agnostic 2Myeloid 2Gynecologic 2Lymphoid 1Dermatologic 1CNS 1

Conditions

Lymphoma, Non-Hodgkin 1

Interventions

Rituximab 227Cyclophosphamide 142fludarabine 69Vincristine 66Methotrexate 62Doxorubicin 54fludarabine phosphate 53Lenalidomide 49Etoposide 49Cytarabine 48Prednisone 47Dexamethasone 44Filgrastim 43Bortezomib 38Whole-Body Irradiation 34Gemcitabine 34Melphalan 32Radiotherapy 30ibrutinib 29Granulocyte Colony-Stimulating Factor 29Alemtuzumab 29obinutuzumab 28Tacrolimus 28Mycophenolic Acid 28Antilymphocyte Serum 28venetoclax 27Calcium Dobesilate 27Busulfan 27Bendamustine Hydrochloride 27idelalisib 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Injections × Lymphoid × Clear all
NCT00089284 2019-08-14

Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL

Northwestern University

Phase 1/2 Terminated
30 enrolled 12 charts
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡